HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Elasy, T. PubMed Articles by Elasy, T. Related Collections Related Articles Social Bookmarking                What's this?

Change as a Constant

The first 20% of the full text of this article appears below.

Part of the widespread interest in the care of individuals with diabetes surrounds the unprecedented changes that have occurred in the field. These changes have attracted the attention and efforts of investigators, businesses, and clinicians. Over the past dozen years, these changes have spanned the fields of pharmacotherapy, approaches to care, and supplies used to support care. This issue of Clinical Diabetes highlights some of those changes.

John R. White, Jr., PA, PharmD, summarizes a new class of medications aimed at raising endogenous levels of incretins—a class of hormones that is just being introduced in medical school curriculums (p. 53). Although we've known for decades about the differential insulin response to oral versus intravenous glucose, there was little appreciation that a class of gut hormones (incretins) was, in part, mediating the increased insulin response to oral glucose. During the past decade, the hormones, receptors, and enzymes responsible for regulating the hormone levels have been identified. Moreover, two products have come to market that leverage our understanding of . . . [Full Text of this Article]

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Articles:

Dipeptidyl Peptidase-IV Inhibitors: Pharmacological Profile and Clinical Use

John R. White, Jr.
Clin. Diabetes 2008 26: 53-57. [Abstract] [Full Text] [PDF]